BioSpace News Archive

MRO Corporation (MRO), a leader in the secure, compliant and efficient exchange of protected health information (PHI), announced today the completion of an investment transaction with Parthenon Capital (Parthenon), a growth-oriented private equity firm

Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer, the company announced today.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on November 6, 2019, to provide a business update and review the Company’s financial results for the third quarter ended September 30, 2019.

Tetra Natural Health (“TNH”) a whollyowned subsidiary of Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF) is pleased to provide an update on its initiatives to bring its Awaye™ topical product for pain relief to the market globally and its activities to commercialize additional natural health products and non-prescription drugs in Canada and the USA.

Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, today announced the company will be exhibiting at the American Society of Nephrology (ASN) Scientific Exposition taking place in Washington DC next week.

Shriners Hospitals and Leading Telegenomics Provider Team Up to Return Actionable Genetic Findings for Pediatric Patients

Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops, today announced that it will release its third-quarter 2019 financial and business results after market close on November 6, 2019.

RareCyte announces the launch of a new RarePlex® Staining Kit, enabling customers to evaluate prostate cancer specific expression of ARv7 on circulating tumor cells (CTC) in their own laboratory.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that Greg Merril, CEO and co-founder of APT, will present an overview of the company and its phage therapy and technologies to investors at the upcoming 2019 World Antimicrobial Resistance Congress, taking place at the Renaissance Hotel in Washington, DC, from November 7 – 8.

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has signed an agreement with Worldwide Clinical Trials (Worldwide), a leading Contract Research Organization (CRO), to conduct a clinical trial to evaluate safety and efficacy in Alzheimer’s Disease.